ZyVersa Therapeutics Inc (ZVSA) Actualités

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell...

Form 8-K - Current report

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases...

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases...

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Lead indication for ZyVersa’s Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications...

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

WESTON, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a...

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material